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Background: ETC-1002, a novel oral drug that regulates imbalances in lipid and carbohydrate metabolism, is being developed to treat 
hypercholesterolemia and other cardio-metabolic risk factors.
methods: Multiple ascending doses of ETC-1002 were evaluated in 56 healthy subjects, some with mildly elevated low density lipoprotein-
cholesterol (LDL-C; >100 mg/dL), in two Phase 1, randomized, double-blind (sponsor open), placebo (PBO)-controlled studies. Seven cohorts of 8 
subjects (6 active, 2 PBO) were treated for 14 days in the clinic with doses of 20 to 220 mg/day of ETC-1002 or PBO.
results: All subjects (93% male, mean age 36 years) with baseline LDL-C levels (mean/group) ranging from 100 to 138 mg/dL completed 
treatment. No clinically meaningful trends were identified in adverse events, clinical labs, vital signs or electrocardiograms related to treatment. 
ETC-1002 consistently lowered LDL-C in a dose related manner up to 36% (p<0.001) at the highest dose. The pharmacokinetics of ETC-1002 and its 
active metabolite showed increases in maximum concentration and area under the curve (AUC0-24 hour) with increasing dose; mean half-life values 
ranged from 16-33 hours.
Percent Change from Baseline in LDL-C 
Study #1
Treatment N Least Squares Mean (SE) Difference from PBO p-value* 
20 mg 6 3.5 (5.0) -7.1 0.298
60 mg 6 -11.2 (5.1) -21.8 0.004
100 mg 6 -16.5 (5.1) -27.1 <0.001
120 mg 6 -15.0 (5.0) -25.6 <0.001
PBO 8 10.6 (4.5)
Study #2
140 mg 6 -21.3 (5.4) -25.7 0.001
180 mg 6 -27.1 (5.4) -31.5 <0.001
220 mg 6 -36.1 (5.4) -40.5 <0.001
PBO 6 4.4 (5.4)
*versus PBO using a mixed model repeat measures analysis
conclusion: ETC-1002 in a daily dose of up to 220 mg for 14 days was safe, well-tolerated and significantly reduced LDL-C in Phase 1 studies; 
pharmacokinetics support once daily dosing. These results provide a wide dosing range for Phase 2 testing in different populations with cardio-
metabolic risk factors.
